Plus Accounts Payable from 2010 to 2025
PSTV Stock | USD 0.73 0.05 7.35% |
Accounts Payable | First Reported 2001-06-30 | Previous Quarter 6.4 M | Current Value 6.9 M | Quarterly Volatility 591.5 M |
Check Plus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Plus Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 337.7 K, Selling General Administrative of 10.2 M or Selling And Marketing Expenses of 637 K, as well as many indicators such as Price To Sales Ratio of 1.22, Dividend Yield of 0.0022 or Days Sales Outstanding of 46.47. Plus financial statements analysis is a perfect complement when working with Plus Therapeutics Valuation or Volatility modules.
Plus | Accounts Payable |
Latest Plus Therapeutics' Accounts Payable Growth Pattern
Below is the plot of the Accounts Payable of Plus Therapeutics over the last few years. An accounting item on the balance sheet that represents Plus Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Plus Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Plus Therapeutics' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Plus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Accounts Payable | 10 Years Trend |
|
Accounts Payable |
Timeline |
Plus Accounts Payable Regression Statistics
Arithmetic Mean | (54,030,376) | |
Coefficient Of Variation | (417.88) | |
Mean Deviation | 105,830,703 | |
Median | 1,297,000 | |
Standard Deviation | 225,784,740 | |
Sample Variance | 50978.7T | |
Range | 909M | |
R-Value | 0.43 | |
Mean Square Error | 44657.9T | |
R-Squared | 0.18 | |
Significance | 0.1 | |
Slope | 20,253,556 | |
Total Sum of Squares | 764681.2T |
Plus Accounts Payable History
About Plus Therapeutics Financial Statements
Plus Therapeutics investors use historical fundamental indicators, such as Plus Therapeutics' Accounts Payable, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Plus Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Accounts Payable | 5.5 M | 5.7 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.